Raanana, Israel, March  25, 2026  (GLOBE NEWSWIRE) --  Polyrizon Ltd. (NASDAQ:PLRZ) (&#34;Polyrizon&#34; or the &#34;Company&#34;), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced

PLRZ

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon Files Annual Report Highlighting Key Development Areas in Biotech

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Raanana, Israel, March  25, 2026  (GLOBE NEWSWIRE) --  Polyrizon Ltd. (NASDAQ:PLRZ) (&amp;#34;Polyrizon&amp;#34; or the &amp;#34;Company&amp;#34;), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Polyrizon Ltd. has filed its Annual Report on Form 20-F with the SEC, detailing fiscal year 2025 operations and development plans. This report may enhance investor confidence in Polyrizon&#039;s ongoing innovation in intranasal protective solutions, potentially influencing stock performance positively.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Polyrizon filed its Annual Report on Form 20-F with the SEC.</li><li>The report covers the fiscal year ended December 31, 2025.</li><li>Polyrizon develops innovative intranasal protective solutions against viruses.</li><li>The company operates in the pre-clinical stage with hydrogel technology.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Securities and Exchange Commission (SEC)</strong>: The filing of the report is a regulatory compliance step.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under Corporate Developments, as it reflects Polyrizon&#039;s regulatory compliance and strategic operational updates which influence its market standing.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Annual report may shift investor sentiment positively.</li><li>Updates on product development could stimulate stock price momentum.</li><li>Increased transparency from the report might attract institutional investors.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Polyrizon&#039;s 20-F annual report was filed on March 24, 2026.</li><li>The fiscal year ended December 31, 2025.</li><li>The company specializes in intranasal hydrogel solutions.</li><li>Polyrizon intended to enhance drugs&#039; nasal delivery with ongoing research.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy PLRZ on potential market interest following the annual report release.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>Raanana, Israel, March  25, 2026  (GLOBE NEWSWIRE) --  Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PLRZ">PLRZ</a>) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the &#34;SEC&#34;).</p>  <p>The report is available on the SEC&#39;s website, at <a href="https://www.globenewswire.com/Tracker?data=sNM2Mr4kjbRS7LpUoIOWdWvwBo4cm1w2MDRqh18mkDK-Wo3Bc_JKk48qHx3SDCYlDfh6YLcJAKhcB65LcY83tiIQiCnylFehMnv1gnRlsyR1wWTlVrA1Fu-tn3CSDNij3AxyC6fpq8t0mx2udoeMVVFI86ZlsA2xvrJWgIZlB_tL8Y_qrD_pwqLedFUVJw_s4cx1xqBqnmiA7DJf-NGnqhUoZw4IIGbY-oH6hi13udw=" rel="nofollow" target="_blank"><u>www.sec.gov</u></a> and Polyrizon's Investor Relations website, at <a href="https://www.globenewswire.com/Tracker?data=xtY2nAjtMiZ9w49-K_OHDHJ-HOcRRUzHLDUGzY3VipVBesRCCaEJrtEI0sj7FAyUoxRPT8RK_DEFtCAsKzy4uFuIY5N23MCg1VONKrh-s16mKj7hFRhgLwijAiHP-FgZxW65p800eBQ98BqeOU_8oSNpe4lZq8BvJtvVON-Bpql7jOtAJ1mVfDa4FtuRKKeCW35KkT5NwQND8xt5Z4prXkbn8wSwe9V7WB9qEfvQJClj2pK0psb5EPbFqn6jXgJCxd5PB3GufOSX09v__mSoTEaMc6F2K2PYogPlgy-Vkt95XbUUvf5ZfHydcaUtteAHNmQyaW6ZNktR8TzFabTZ71KIGbUKvDoZdGxJ0X65pKo=" rel="nofollow" target="_blank"><u>https://investor.polyrizon-biotech.com/</u></a>.</p>  <p>Shareholders can obtain copies of Polyrizon's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Polyrizon's Investor Relations Department at <a href="https://www.globenewswire.com/Tracker?data=uG8kBsPgJUUVPn3p1gh_dDYmuPi1LT2v2Sf84KpQS_Z7gwTaSD9Gy3jWBkGLUMBh7V0CsN-h4ip0zRfRHW8Xmkv2eZ2cOz6-jjiLcmNXgnFJQzK4bW8IRwRkE-kOhb1hltgu6f6m48y-d1fstFgQoFfecOgFQUttv6CqHT6Pr2u4QJDTEmc0gJgoaXNUwu47Ji5AgSVPX4VYXCHflvljAuCELiUID_wgErUHsXgRaqCCehSjihlsAm5SLeaaqQyTx1EFsjE2Nzb5odK9e6QyFdKFjIswr8Wj7xHhBi_SOSs=" rel="nofollow" target="_blank"><u>IR@polyrizon-biotech.com</u></a>.</p>  <p><b>About Polyrizon</b></p>  <p>Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon's proprietary Capture and Contain TM, or C&amp;C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a "biological mask" with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&amp;C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target &#x2122;, or T&amp;T. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=xtY2nAjtMiZ9w49-K_OHDGl-iIJMYIcJKx1rHuUgZ9K96Ot9HCsPqHpAZyGTgm0ROKaAaV7MMoMRoVHbKFGyxCrRRRCZXdkXfkyRxXMLWkJPwqQ1eUqyxXHRI-3dWxLWtj6iHisBHD3_Oy9KbHw-KVGG_PA0eTSei68bCzkwABApI3h9Rd1z9PqUftb-FgEhrVMhSyyPV-ej15dUY6DEQBckT4fCDjdCy4Du6VYFV2ePArm_T8f2rr4STiDFSWfmd-C2XL5YEJVjn-y2OMMA6pxTuZaYjfHpzr5VxvZGlyJepQRXyskGe2SNyXqQJn9t" rel="nofollow" target="_blank"><u>https://polyrizon-biotech.com</u></a>.</p>  <p><b>Forward Looking Statements</b></p>  <p>This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's annual report filed with the SEC on March 24, 2026 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.</p>  <p>Contacts:</p>  <p>Michal Efraty<br></br>Investor Relations<br></br><a href="https://www.globenewswire.com/Tracker?data=uG8kBsPgJUUVPn3p1gh_dDYmuPi1LT2v2Sf84KpQS_YMepDjYo7dMT1dnc5k5ZZ-XkWYBt9lwmVjmM2c4GDmLeeQAXNLHvZh57n4kUuAncL6HBKKRgIRGz5vT5yVpRESz7qgTASBMeoXB0jQA1WGtRPiiQWd75VDapBhD61pabo9z2580jaXz_XqsJlZx6vWE95TaeeCArf2KNrc9xREXvzarAmvfb9AwnpAQEf3rr13SmE2KTQ8Y4aKoIDQAtZBHx_wHakv1GmzZmUYYyrkmUSLgDxxMes9pvbEM9bExcs=" rel="nofollow" target="_blank"><u>IR@polyrizon-biotech.com</u></a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3ODc1OCM3NTA0Mzk3IzUwMDEyOTIyMw=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/OTE5YTFhYzYtNzc1OS00ZDkzLTlkYjctYjg5MDFhNzIxMDMyLTUwMDEyOTIyMy0yMDI2LTAzLTI1LWVu/tiny/Polyrizon-Ltd-.png" referrerpolicy="no-referrer-when-downgrade"></img>

Polyrizon Ltd. has filed its Annual Report on Form 20-F with the SEC, detailing fiscal year 2025 operations and development plans. This report may enhance investor confidence in Polyrizon's ongoing innovation in intranasal protective solutions, potentially influencing stock performance positively.

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News